title: 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
abstract: To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.
authors.affiliation: Department of Medical Oncology, West German Cancer Centre, University Hospital, University Duisburg-Essen, Ruhrlandklinik, Essen, Germany.
authors.forename: W E E
authors.initials: WE
authors.lastname: Eberhardt
authors.affiliation: Department of Radiation Oncology, KU Leuven-University of Leuven, University Hospitals Leuven, Leuven, Belgium.
authors.forename: D
authors.initials: D
authors.lastname: De Ruysscher
authors.affiliation: Division of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland.
authors.forename: W
authors.initials: W
authors.lastname: Weder
authors.affiliation: Department of Radiation Oncology, Gustave Roussy Cancer Institute, Villejuif, France.
authors.forename: C
authors.initials: C
authors.lastname: Le Péchoux
authors.affiliation: Department of Thoracic Surgery, University Hospitals, KU Leuven, Leuven, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: De Leyn
authors.affiliation: Department of Thoracic Surgery, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Hoffmann
authors.affiliation: Department of Chest Disease, University Hospital, Besançon, France.
authors.forename: V
authors.initials: V
authors.lastname: Westeel
authors.affiliation: Clinic of Oncology, University Hospital Zürich, Zürich, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Stahel
authors.affiliation: Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Felip
authors.affiliation: Département d'Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Peters
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001999:Bronchoscopy; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D019468:Disease Management; D061765:Endoscopic Ultrasound-Guided Fine Needle Aspiration; D005047:Etoposide / Q000008:administration & dosage; D005060:Europe; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008175:Lung Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D008198:Lymph Nodes / Q000473:pathology; D008482:Mediastinum; D064847:Multimodal Imaging; D011013:Pneumonectomy; D049268:Positron-Emission Tomography; D018714:Radiotherapy, Adjuvant; D012955:Societies, Medical; D014057:Tomography, X-Ray Computed; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin; D000077235:Vinorelbine
keywords: ESMO; locally advanced; non-small-cell lung cancer; recommendations; stage III